Irinotecan
Central Nervous System Ganglioneuroblastoma
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Central Nervous System Ganglioneuroblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
AZD1775 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Fludarabine Beijing Biotech | Phase 1/2 | CCC |
Eb-Dtnb-Nk Beijing Biotech | Phase 1/2 | CCC |
Cyclophosphamide Beijing Biotech | Phase 1/2 | CCC |
FILGRASTIM St. Jude Children's Research Hospital | Phase 1 | CC |
gsk1120212 St. Jude Children's Research Hospital | Phase 1 | CC |
Sonidegib St. Jude Children's Research Hospital | Phase 1 | CC |
Ribociclib St. Jude Children's Research Hospital | Phase 1 | CC |
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →